Beam Therapeutics (NASDAQ:BEAM) Downgraded to Strong Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Beam Therapeutics to “strong sell” from “sell,” contrasting with a broader analyst consensus of “Moderate Buy,” an average $49 price target, and several Buy/Outperform ratings.
• BEAM shares opened at $23.99, near the lower end of their 52-week range, while the company reported a quarterly EPS loss of $1.18 and revenue of just $0.49 million—well below estimates—with revenue down 94.2% year over year.
• Insiders sold 301,527 shares worth approximately $10.5 million over the past 90 days, while institutional investors continued to own nearly all outstanding shares at 99.68%.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Sunday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Tuesday, August 25th. Wedbush restated an "outperform" rating and set a $65.00 price target on shares of Beam Therapeutics in a report on Wednesday. Bank of America reaffirmed a "buy" rating and set a $47.00 price target on shares of Beam Therapeutics in a research report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Beam Therapeutics has an average rating of "Moderate Buy" and an average target price of $49.00.

Beam Therapeutics Stock Down 1.6%

BEAM stock opened at $23.99 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. Beam Therapeutics has a fifty-two week low of $20.23 and a fifty-two week high of $38.26. The stock's 50 day simple moving average is $28.50 and its 200 day simple moving average is $28.88. The company has a market cap of $2.48 billion, a P/E ratio of -27.90 and a beta of 2.22.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.07). Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%.The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. During the same quarter in the prior year, the business posted ($1.00) EPS. The firm's revenue for the quarter was down 94.2% on a year-over-year basis. On average, research analysts expect that Beam Therapeutics will post -4.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Amy Simon sold 16,667 shares of Beam Therapeutics stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the sale, the insider directly owned 85,696 shares in the company, valued at $2,205,815.04. The trade was a 16.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Fmr Llc sold 251,488 shares of the company's stock in a transaction on Friday, June 26th. The stock was sold at an average price of $35.26, for a total value of $8,867,466.88. Following the completion of the sale, the insider directly owned 854,583 shares in the company, valued at approximately $30,132,596.58. The trade was a 22.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 301,527 shares of company stock valued at $10,468,500. 3.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in Beam Therapeutics in the second quarter worth about $43,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Beam Therapeutics in the 4th quarter worth approximately $47,000. Hollencrest Capital Management purchased a new stake in shares of Beam Therapeutics in the 1st quarter worth approximately $43,000. Larson Financial Group LLC grew its stake in shares of Beam Therapeutics by 4,370.5% in the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company's stock worth $48,000 after buying an additional 1,923 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Beam Therapeutics during the 4th quarter valued at approximately $59,000. 99.68% of the stock is currently owned by institutional investors.

Key Headlines Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Analysts maintain bullish views. Wedbush reaffirmed its Buy/Outperform rating, while Canaccord Genuity and JonesTrading also maintained Buy ratings. Separately, the brokerage consensus remains “Moderate Buy,” supporting investor confidence in Beam’s pipeline and long-term prospects. Wedbush Reaffirms Their Buy Rating Wedbush Reiterates Outperform Rating Consensus Moderate Buy Rating
• Positive Sentiment: BEAM-302 data show sustained biomarker improvement. Updated Phase 1/2 results in alpha-1 antitrypsin deficiency indicated that the investigational treatment restored AAT levels, with biomarker follow-up extending to 18 months. The results strengthen the case for continued development, although the study remains early stage and clinical benefit has not yet been conclusively established. BEAM-302 Clinical Data Analysis
• Neutral Sentiment: Options activity increased. Unusually large options trading was reported, which may signal heightened speculation or hedging but does not establish a clear directional outlook for BEAM. Unusually Large Options Trading
• Neutral Sentiment: Reports of a sharp increase in short interest showed zero shares both before and after the period, suggesting a data-quality issue rather than a meaningful change in bearish positioning.
• Negative Sentiment: Pomerantz LLP is investigating potential investor claims. The law firm’s announcement may add legal and headline risk, although it does not allege that Beam has been found liable. Pomerantz Investor Investigation

Beam Therapeutics Company Profile

Beam Therapeutics Inc is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.